Email: npveliotes@doctorsenroute.com
Cell: +27 82 451 2810
Areas of expertise:
Doctors Enroute Dr NP Veliotes 082 451 2810
Doctors Enroute is an organization based in Johannesburg which has its primary mission to provide the highest medical care. Contact Us – npveliotes@doctorsenroute.com
Socialize With Us
This is a message to the admin. Your website is missing out on at least 300 visitors per day. I have found a company which offers to dramatically increase your visitors to your website: http://go.avmsapp.at/1r5y They offer 500 free visitors during their free trial period and I managed to get over 15,000 visitors per month using their services, you could also get lot more targeted traffic than you have now. Hope this helps 🙂 Take care.
Hello Web Admin, I noticed that your On-Page SEO is is missing a few factors, for one you do not use all three H tags in your post, also I notice that you are not using bold or italics properly in your SEO optimization. On-Page SEO means more now than ever since the new Google update: Panda. No longer are backlinks and simply pinging or sending out a RSS feed the key to getting Google PageRank or Alexa Rankings, You now NEED On-Page SEO. So what is good On-Page SEO?First your keyword must appear in the title.Then it must appear in the URL.You have to optimize your keyword and make sure that it has a nice keyword density of 3-5% in your article with relevant LSI (Latent Semantic Indexing). Then you should spread all H1,H2,H3 tags in your article.Your Keyword should appear in your first paragraph and in the last sentence of the page. You should have relevant usage of Bold and italics of your keyword.There should be one internal link to a page on your blog and you should have one image with an alt tag that has your keyword….wait there’s even more Now what if i told you there was a simple WordPress plugin that does all the On-Page SEO, and automatically for you? That’s right AUTOMATICALLY, just watch this 4minute video for more information at. Seo Plugin
I discovered your Doctors Enroute Dr NP Veliotes 082 451 2810 | Doctors Enroute is an organization based in Johannesburg which has its primary mission to provide the highest medical care. Contact Us – npveliotes@doctorsenroute.com page and noticed you could have a lot more visitors. I have found that the key to running a website is making sure the visitors you are getting are interested in your niche. There is a company that you can get visitors from and they let you try their service for free. I managed to get over 300 targeted visitors to day to my website. Visit them today: http://www.trumk.com/id
hermes bags outlet store replica hermes constance handbags vintage zevmczggh
Please inform. Product line.
Boston, MA usa
U.S.
Potential Zika Virus Therapies Identified by Researchers
Several candidates found from among 6,000 drugs already commercially available or undergoing clinical trials. A researcher performs experiments to test whether already existing drugs might be effective in treating Zika-virus infection, as part of a recent study.
The research, published in the journal Nature Medicine, could help quicken discovery of medications for Zika and help prevent the neurological disorders associated with it, including microcephaly, a condition in which babies are born with abnormally small heads associated with improper brain development.
The new paper identifies about a dozen substances, including a long-used treatment for worm infections, that suppress the pathogen’s replication. Another molecule, currently in clinical trials for liver disease, prevents brain cells in a dish from dying following Zika exposure, a potentially important result given the fetal-brain defects associated with the virus. The study also suggests combinations of these two classes of compounds could be the most effective way to treat Zika.
Mosquitoes have infected at least 14 people in Miami with the Zika virus. Officials believe local transmission remains isolated to a one-square-mile area in Miami-Dade County. How can Zika be contained?
Health officials grappling with the Zika virus in Florida face a mystery: a pregnant woman who set off the Zika scare is not connected to a one square-mile area where officials have identified the virus.
Simply preventing cell death could lead to chronic infection, so it is also important to keep the virus from spawning, said Mariano Garcia-Blanco, a virologist at the University of Texas Medical Branch in Galveston. He wasn’t involved with the research.
Commercial drugs are rarely tested on pregnant women, so it is unknown if the new results would help mothers and their fetuses directly, experts said.
“For drug development, pregnancy is a very dangerous place people don’t touch,” said Hongjun Song, a neuroscientist at Johns Hopkins University School of Medicine in Baltimore and one of the lead authors on the study. “Here, we don’t really have a choice. We have a jump-start, [but]…there’s a lot more to do.”
The team tested drug candidates in stem cells and so-called brain organoids, mini reconstructions of the developing brain. They will need to validate their findings in animal models and ultimately people.
Apart from niclosamide, the worm-killing medication, it is unlikely the molecules shown to halt viral replication would be approved for pregnant women because of potential toxic effects on the fetus. But, virologists said, treating men and nonpregnant women could decrease a pregnant woman’s risk of infection by reducing the amount of virus circulating in people around them.
The work is part of a recent trend known as drug repurposing. Rather than engineer compounds from scratch, scientists sift through multitudes of already existing ones to see if any can treat a particular disease.
This approach “is particularly useful for urgent [situations],” like the Zika epidemic, during which scientists don’t have time to undergo the lengthy drug-discovery process, said Wei Zheng, a researcher at the National Institutes of Health’s National Center for Advancing Translational Sciences and one of the study’s lead authors.
To move the research forward, the team will begin conducting animal studies shortly, according to Dr. Zheng. They will also test another 80,000 compounds with the help of robots, according to an NIH spokesman.
The researchers have filed a patent covering the new findings. The goal is to incite companies to commercialize the research and develop Zika-busting drugs, said the NIH spokesman.
Pharmaceutical company Spotlight Innovation Inc. will fund some of the research team’s future work through a partnership with Florida State University’s Hengli Tang, another of the study’s lead authors, according to Geoffrey Laff, Spotlight’s senior vice president of business development. The financial details weren’t disclosed, but amount to “several years of funding,” Dr. Laff said. Spotlight would license any resulting intellectual property, he added.
The licensing may get complicated if the results involving liver-disease drug emricasan hold up, and comparable alternatives aren’t found. The compound prevented cell death most potently among molecules tested in the study.
Conatus Pharmaceuticals Inc. has several patents for emricasan. Some don’t expire until 2028. A third party wanting to sell the molecule would need to license it from Conatus, according to Joseph O’Malley, global chair for intellectual property at Paul Hastings LLP.
“Assuming that drug were to be found to treat Zika,” Mr. O’Malley said, “it would be bad news for the company. It would be under tremendous pressure to license it for little or no money.”
Alfred Spada, Conatus’s chief scientific officer, said if emricasan “were effective in the treatment of such a devastating disease, I think we would be ecstatic.”